Femoropopliteal

EMINENT Trial | Stent Eluvia vs BMS in Femoropopliteal Territory

Endovascular therapy in femoropopliteal territory has become the standard, mainly with self-expanding stents, aimed at preventing early...

Results of the COMPARE Study After 2 Years: Low Dose vs. High Dose Paclitaxel-Coated Balloons

The development of new devices and techniques has expanded the range of patients who benefit from endovascular...

Clinical Results of IVUS-Guided Drug-Eluting Stent Implantation in Femoropopliteal Disease

Endovascular treatment of femoropopliteal lesions has become the first-line treatment due to the development of devices that...

DISRUPT-PAD III: Followup of IVL Treatment in Femoropopliteal Territory

Femoropopliteal segment calcification can generate complications for both preparation and execution of endovascular therapies for patients with...

Intermittent Claudication: Invasive Treatment Superior to Pharmacological Treatment?

Peripheral vascular disease is strongly associated to cardiovascular events and a negative impact on health status and...

IN.PACT Global: Follow Up of Real-Life Patient in Femoropopliteal Territory

Drug coated balloons (DCB) emerged as an innovative treatment approximately 10 years ago. Since then, numerous randomized...

Should We Start Stenting with DES in Femoropopliteal Territory?

Percutaneous intervention of femoropopliteal lesions have been the standard strategy these past two decades. The development of...

IVUS in Femoropopliteal PCI: Should We Start Using It?

For approximately two decades now, PCI has been the treatment of choice in femoropopliteal territory, and even...